Phyllis Gotlib Sells 3,707 Shares of American Well (NYSE:AMWL) Stock

American Well Corporation (NYSE:AMWL) insider Phyllis Gotlib sold 3,707 shares of American Well stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $4.85, for a total transaction of $17,978.95. Following the sale, the insider directly owned 119,870 shares in the company, valued at approximately $581,369.50. This trade represents a 3.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Phyllis Gotlib also recently made the following trade(s):

• On Monday, December 1st, Phyllis Gotlib sold 3,574 shares of American Well stock. The shares were sold at an average price of $4.06, for a total transaction of $14,510.44.

American Well Trading Up 3.0%

NYSE:AMWL opened at $5.37 on Wednesday. The company has a market cap of $87.86 million, a P/E ratio of -0.75 and a beta of 1.26. American Well Corporation has a twelve month low of $3.71 and a twelve month high of $12.95. The company’s 50-day moving average price is $4.42 and its 200-day moving average price is $6.13.

American Well (NYSE:AMWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($1.74) EPS for the quarter, beating analysts’ consensus estimates of ($1.83) by $0.09. American Well had a negative net margin of 42.80% and a negative return on equity of 39.80%. The company had revenue of $56.29 million during the quarter, compared to the consensus estimate of $54.56 million. On average, analysts expect that American Well Corporation will post -9.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AMWL. Headlands Technologies LLC purchased a new position in American Well during the second quarter worth about $39,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of American Well during the 3rd quarter worth approximately $62,000. Prelude Capital Management LLC acquired a new stake in American Well in the 3rd quarter valued at approximately $86,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in American Well in the 2nd quarter valued at approximately $89,000. Finally, Engineers Gate Manager LP purchased a new stake in American Well in the second quarter valued at approximately $101,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMWL. Wall Street Zen lowered American Well from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Morgan Stanley lowered their price target on shares of American Well from $10.50 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of American Well in a report on Wednesday, October 8th. Wells Fargo & Company reduced their target price on shares of American Well from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Stifel Nicolaus decreased their target price on shares of American Well from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Wednesday, November 5th. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.58.

About American Well

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.